Welcome to our dedicated page for Anaptysbio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on Anaptysbio stock.
AnaptysBio, Inc. (Nasdaq: ANAB) generates a steady flow of news as a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. News coverage on this page centers on its internal pipeline, royalty-bearing collaborations, corporate strategy and legal developments.
Investors following ANAB news will see updates on rosnilimab, a pathogenic T cell depleter that has completed a Phase 2b trial in rheumatoid arthritis and has been evaluated in ulcerative colitis, as well as early-stage programs ANB033 and ANB101. Company announcements describe clinical data readouts, safety and efficacy findings, and decisions to advance or discontinue specific trials, such as the discontinuation of a Phase 2 ulcerative colitis study after not meeting primary and key secondary endpoints at Week 12.
Another key news theme is AnaptysBio’s financial collaborations. Releases detail royalty and milestone expectations from Jemperli (dostarlimab-gxly), the PD-1 antagonist licensed to GSK through Tesaro, and from imsidolimab, the IL-36 receptor antagonist licensed to Vanda Pharmaceuticals. Updates from partners, such as Vanda’s Biologics License Application submission for imsidolimab, also feature prominently because AnaptysBio holds the underlying license.
Corporate and capital allocation developments appear in ANAB news as well, including the company’s intent to separate its biopharma operations from its substantial royalty assets by the end of 2026 and board-authorized stock repurchase plans. Legal and regulatory items, such as AnaptysBio’s litigation with Tesaro and GSK over the Jemperli collaboration and related SEC Form 8-K filings, also contribute to the news flow. This page aggregates these announcements so readers can track how clinical results, royalty assets, strategic separation plans and legal proceedings may shape AnaptysBio’s trajectory over time.
Anaptys (Nasdaq: ANAB) announced the approved spin-off of First Tracks Biotherapeutics (TRAX), expected to begin regular trading on April 20, 2026. Anaptys stockholders will receive one share of TRAX per one share of ANAB (record date April 6, 2026). First Tracks launches with $180 million in cash (including an $80 million private placement) and an initial two-year cash runway to advance three lead clinical programs.
First Tracks Biotherapeutics (Nasdaq: ANAB) secured commitments of $145 million in a private placement, including $80 million in gross proceeds to the company from sale of 5,791,478 primary shares at $13.81 per share. First Tracks Bio is expected to spin off on April 20, 2026 and to launch with $180 million in cash, providing an estimated two-year cash runway. Proceeds will fund general corporate purposes, including clinical development of ANB033. The financing involves institutional investors and placement agents Leerink, Barclays and UBS.
Anaptys (NASDAQ: ANAB) announced a $100 million stock repurchase plan and a business update ahead of the planned spin-off of First Tracks Biotherapeutics (TRAX) targeted for April 20, 2026. Post-spin-off, Anaptys will manage royalty and financial collaborations for Jemperli and imsidolimab, operate with ~10 FTEsannualized expenses <$10M and initial net cash and investments of approximately $140–$145M.
The company appointed Susannah Gray to the board, engaged Piper Sandler as exclusive financial advisor, and anticipates paying down remaining non-recourse debt to Sagard by end of Q2 2027.
Anaptys (Nasdaq: ANAB) announced a planned Q2 2026 spin-off of its biopharma portfolio into a new public company, First Tracks Biotherapeutics (TRAX), while retaining a royalty-management company under the Anaptys name.
Key financials: year-end cash and investments of $311.6M, Q4 2025 net income of $49.6M, and full-year 2025 net loss of $13.2M. Jemperli sales reached $343M in Q4 2025, implying a ~$1.4B annualized run rate and potential >$390M annualized royalties to Anaptys at GSK peak guidance.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced FDA acceptance of its Biologics License Application for imsidolimab to treat Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026.
Pivotal GEMINI-1/2 studies showed 53% achieving GPPPGA 0/1 at Week 4 versus 13% placebo; efficacy maintained during ~2-year monthly maintenance, with a favorable safety profile and low anti-drug antibodies.
Anaptys (Nasdaq: ANAB) announced that its CEO Daniel Faga and other executives will participate in multiple investor conferences in February–March 2026, including Guggenheim, Piper Sandler, TD Cowen, Barclays, UBS, and Leerink.
Live fireside chats and 1x1 meetings are scheduled; webcasts will be available on the company's investor website with replays for at least 30 days.
Summary not available.
Anaptys (Nasdaq: ANAB) announced that Daniel Faga, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.
A live webcast will be available on the company's investor site at https://ir.anaptysbio.com/presentations-and-events, with a replay available for at least 30 days after the event.
Vanda Pharmaceuticals (Nasdaq: VNDA) submitted a Biologics License Application (BLA) to the FDA on Dec 15, 2025 for imsidolimab to treat generalized pustular psoriasis (GPP).
The BLA is supported by positive global Phase 3 GEMINI-1 and GEMINI-2 results: a single intravenous dose produced rapid clearance (clear or almost clear skin) with efficacy maintained during an approximately 2-year maintenance period with monthly dosing, and a favorable safety profile with no clinically meaningful safety signals reported. Vanda requested priority review, which could enable FDA action as early as mid-2026 if granted.
Anaptys (Nasdaq: ANAB) said CEO Daniel Faga and other executives will participate in multiple December investor conferences, including a fireside chat and 1x1 meetings at the Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 1:30 PM ET and the Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 3, 2025 at 7:55 AM ET.
Live webcasts of the fireside chats will be available on the company investor website and replays will be available for at least 30 days after each event.